An Autotaxin/Lysophosphatidic Acid/Interleukin‐6 Amplification Loop Drives Scleroderma Fibrosis

We previously implicated the lipid mediator lysophosphatidic acid (LPA) as having a role in dermal fibrosis in systemic sclerosis (SSc). The aim of this study was to identify the role of the LPA‐producing enzyme autotaxin (ATX), and to connect the ATX/LPA and interleukin‐6 (IL‐6) pathways in SSc.

[1]  Jaclyn N. Taroni,et al.  Identification of Optimal Mouse Models of Systemic Sclerosis by Interspecies Comparative Genomics , 2016, Arthritis & rheumatology.

[2]  Tammara A. Wood,et al.  Myofibroblasts in Murine Cutaneous Fibrosis Originate From Adiponectin‐Positive Intradermal Progenitors , 2015, Arthritis & rheumatology.

[3]  V. Poletti,et al.  Combination therapy: the future of management for idiopathic pulmonary fibrosis? , 2014, The Lancet. Respiratory medicine.

[4]  Anuh T. George,et al.  Blockade of IL-6 Trans Signaling Attenuates Pulmonary Fibrosis , 2014, The Journal of Immunology.

[5]  C. Denton,et al.  SAR100842, an Antagonist of Lysophaphatidic Acid Receptor 1, As a Potential Treatment for Patients with Systemic Sclerosis: Results from a Phase 2a Study. , 2014 .

[6]  M. Montès,et al.  Targeting IL-6 by both passive or active immunization strategies prevents bleomycin-induced skin fibrosis , 2014, Arthritis Research & Therapy.

[7]  Tammara A. Wood,et al.  Myofibroblasts in Cutaneous Fibrosis Originate from Adiponectin-Positive Intradermal Progenitors Running Head: Adipocytemyofibroblast transition (AMT) in skin fibrosis , 2014 .

[8]  J. Saulnier-Blache,et al.  Involvement of autotaxin/lysophosphatidic acid signaling in obesity and impaired glucose homeostasis. , 2014, Biochimie.

[9]  M. Mayes,et al.  An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative , 2013 .

[10]  A. Rezza,et al.  Enpp2/Autotaxin in Dermal Papilla Precursors is Dispensable for Hair Follicle Morphogenesis , 2013, The Journal of investigative dermatology.

[11]  G. Prestwich,et al.  Pulmonary autotaxin expression contributes to the pathogenesis of pulmonary fibrosis. , 2012, American journal of respiratory cell and molecular biology.

[12]  D. Abraham,et al.  Clinical and pathological significance of interleukin 6 overexpression in systemic sclerosis , 2012, Annals of the rheumatic diseases.

[13]  Y. Shimomura.  Congenital hair loss disorders: Rare, but not too rare , 2012, The Journal of dermatology.

[14]  Y. Shima,et al.  Growth Factors , Cytokines , and Cell Cycle Molecules Blockade of Interleukin-6 Receptor Alleviates Disease in Mouse Model of Scleroderma , 2011 .

[15]  W. Gerald,et al.  Stat3 Mediates Expression of Autotaxin in Breast Cancer , 2011, PloS one.

[16]  J. Scheller,et al.  The soluble Interleukin 6 receptor: generation and role in inflammation and cancer. , 2011, European journal of cell biology.

[17]  D. Lorrain,et al.  Amelioration of dermal fibrosis by genetic deletion or pharmacologic antagonism of lysophosphatidic acid receptor 1 in a mouse model of scleroderma. , 2011, Arthritis and rheumatism.

[18]  P. Valet,et al.  Adipose-specific disruption of autotaxin enhances nutritional fattening and reduces plasma lysophosphatidic acid , 2011, Journal of Lipid Research.

[19]  M. Fujimoto,et al.  Serum chemokine and cytokine levels as indicators of disease activity in patients with systemic sclerosis , 2011, Clinical Rheumatology.

[20]  Kyoko Noguchi,et al.  LPA receptors: subtypes and biological actions. , 2010, Annual review of pharmacology and toxicology.

[21]  M. Nöthen,et al.  In vitro analysis of LIPH mutations causing hypotrichosis simplex: evidence confirming the role of lipase H and lysophosphatidic acid in hair growth. , 2009, The Journal of investigative dermatology.

[22]  L. Carbone,et al.  Elevated Serum Levels of Arachidonoyl-lysophosphatidic Acid and Sphingosine 1-Phosphate in Systemic Sclerosis , 2009, International journal of medical sciences.

[23]  J. Aoki,et al.  Two pathways for lysophosphatidic acid production. , 2008, Biochimica et biophysica acta.

[24]  S. Pendergrass,et al.  Molecular Subsets in the Gene Expression Signatures of Scleroderma Skin , 2008, PloS one.

[25]  J. Wain,et al.  The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak , 2008, Nature Medicine.

[26]  Kazuhiro Nakamura,et al.  Both Plasma Lysophosphatidic Acid and Serum Autotaxin Levels are Increased in Chronic Hepatitis C , 2007, Journal of clinical gastroenterology.

[27]  Giulio Gabbiani,et al.  The myofibroblast: one function, multiple origins. , 2007, The American journal of pathology.

[28]  H. Arai,et al.  Measurement of lysophospholipase D/autotaxin activity in human serum samples. , 2007, Clinical biochemistry.

[29]  P. Merkel,et al.  Myofibroblasts and hyalinized collagen as markers of skin disease in systemic sclerosis. , 2006, Arthritis and rheumatism.

[30]  Y. Kishi,et al.  Autotaxin Stabilizes Blood Vessels and Is Required for Embryonic Vasculature by Producing Lysophosphatidic Acid* , 2006, Journal of Biological Chemistry.

[31]  C. Mummery,et al.  Autotaxin, a Secreted Lysophospholipase D, Is Essential for Blood Vessel Formation during Development , 2006, Molecular and Cellular Biology.

[32]  J. Salles,et al.  Production of lysophosphatidic acid in blister fluid: involvement of a lysophospholipase D activity. , 2005, The Journal of investigative dermatology.

[33]  P. Clézardin,et al.  Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer. , 2004, The Journal of clinical investigation.

[34]  Hideo Sakamoto,et al.  Inhibition of pulmonary fibrosis by the chemokine IP-10/CXCL10. , 2004, American journal of respiratory cell and molecular biology.

[35]  N. Mukaida,et al.  Essential involvement of IL‐6 in the skin wound‐healing process as evidenced by delayed wound healing in IL‐6‐deficient mice , 2003, Journal of leukocyte biology.

[36]  G. Mills,et al.  Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production , 2002, The Journal of cell biology.

[37]  T. Medsger,et al.  The value of the Health Assessment Questionnaire and special patient-generated scales to demonstrate change in systemic sclerosis patients over time. , 1997, Arthritis and rheumatism.

[38]  G. Ciliberto,et al.  Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment. , 1997, Immunity.

[39]  Richard W. Martin,et al.  Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. , 1995, The Journal of rheumatology.

[40]  C. Kuhn.  The pathogenesis of pulmonary fibrosis. , 1993, Monographs in pathology.

[41]  K. Bost,et al.  Mechanisms of pathogenesis in scleroderma. I. Overproduction of interleukin 6 by fibroblasts cultured from affected skin sites of patients with scleroderma. , 1992, The Journal of rheumatology.

[42]  J. Saurat,et al.  Smooth muscle differentiation in scleroderma fibroblastic cells. , 1990, The American journal of pathology.

[43]  T. Hirano,et al.  Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130 , 1989, Cell.